ZBTB7A Enhances Osteosarcoma Chemoresistance by Transcriptionally Repressing IncRNALINC00473-IL24 Activity

Abstract
Chemoresistance remains a major drawback to osteosarcoma treatment. ZBTB7A, a member of the POK transcription repressor family, was shown to play an important role in tumorigenesis. However, the effect of ZBTB7A on osteosarcoma chemoresistance is completely unknown. In this study, we found that ZBTB7A is increased in cisplatin-resistant osteosarcoma cells and that elevated ZBTB7A inhibits cisplatin-induced apoptosis by repressing LINC00473 expression. Further mechanistic studies revealed that ZBTB7A directly binds to the promoter and suppresses the transcription of LINC00473. Additionally, our data indicate that LINC00473 interacts with the transcript factor C/EBPβ, facilitating its binding to the promoter of IL24, leading to decrease chemoresistance. Thus, these findings indicate that the ZBTB7A-mediated LINC00473-C/EBPβ-IL24 pathway is a promising novel target for overcoming cisplatin resistance in osteosarcoma.

Introduction
Osteosarcoma is the most common type of primary bone cancer that mainly arises in childhood and adolescence [1–3]. Use of chemotherapy along with surgery has improved the overall 5-year survival rate of osteosarcoma patients [4–7]. Cisplatin is the most widely used platinum-based anticancer drug for osteosarcoma, which interacts with nucleophilic N7 sites of purine bases in DNA to induce DNA damage that leads to cell death [2,8,9]. Although this treatment strategy is effective, it is often limited by acquired or intrinsic resistance of cancer cells to the drug. Thus, understanding the molecular mechanisms that lead to chemoresistance is essential to developing more effective treatments against osteosarcoma.

ZBTB7A, also known as Pokemon, LRF, or FBI, is a member of the POK family of transcriptional repressors, which consists of an NH2-terminal POZ/BTB domain and 4 COOH-terminal krüppel-type zinc fingers. The POZ/BTB domain is involved in homodimerization or heterodimerization, and recruits some corepressors such as BcoR, NcoR, or SMRT, while the krüppel-type zinc finger domain mediates specific DNA recognition and binding [10,11]. ZBTB7A was reported to increase in some human cancers, such as breast cancer, colorectal cancer, prostate cancer, bladder cancer, liver cancer, and lung cancer, and to play an important role in tumorigenesis [12,13]. However, some studies have indicated that ZBTB7A acts as a tumor suppressor via repressing glycolysis and metastasis [14,15]. Although different functions have been reported, the effect of ZBTB7A on chemoresistance in osteosarcoma is unclear.

Long noncoding RNAs (lncRNAs) are a class of transcripts longer than 200 nucleotides with no protein-coding capacity and are poorly conserved [16,17]. Several functional lncRNAs were recently shown to play important regulatory roles in various biological processes, including embryonic development, cell migration, cell proliferation, apoptosis, and tumorigenesis [17,18]. Chemoresistance of cancers remains a major reason leading to tumor recurrence. Recently, several lncRNAs were identified to regulate chemoresistance in many cancers, such as lncRNAs HOTAIR [19], MEG3 [20], LINC00161 [9], and AC023115.3 [21].
Figure 1. ZBTB7A inhibited cisplatin-induced apoptosis. (A) The protein levels of ZBTB7A were analyzed in U2OS and U2OSR cells. (B-E) U2OS and U2OSR cells were treated with cisplatin as indicated, and cell lysates were then subjected to Western blotting analysis using the indicated antibodies. (F and G) U2OSR and U2OS cells with or without knocked down ZBTB7A were treated with cisplatin as indicated, and the cell lysates were analyzed by Western blotting with the indicated antibodies. (H) U2OS cells with or without overexpressing ZBTB7A were treated with cisplatin as indicated, and the cell lysates were then subjected to Western blotting analysis using the indicated antibodies. (I and J) U2OS cells with or without knockdown ZBTB7A were treated with cisplatin as indicated. The percentage of cell apoptosis was analyzed by flow cytometry. The data represent the mean ± SD of three independent experiments. **P < .01 versus CTR. (K and L) U2OS cells with or without overexpressed ZBTB7A were treated with cisplatin as indicated. Cell apoptosis was analyzed by flow cytometry. The data represent the mean ± SD of three independent experiments. *P < .05 versus CTR. (M and N) The ZBTB7A zinc finger mutant was constructed (M). U2OS cells with or without overexpressed ZBTB7A or ZBTB7A R399L were treated with cisplatin as indicated, and the cell lysates were then subjected to Western blotting analysis using the indicated antibodies (N).
Although several lncRNAs have been indicated to involve in cancer chemoresistance, the lncRNAs regulated by ZBTB7A were still unknown.

In this study, we found that the expression level of ZBTB7A was increased in cisplatin-resistant osteosarcoma cells and that elevated ZBTB7A enhanced chemoresistance via transcriptionally repressing LINC00473 expression. Additionally, we found that LINC00473 promoted the activity of IL24 promoter and elevated IL24 expression. Further mechanistic studies revealed that LINC00473 interacted with C/EBPβ, thereby facilitating IL24 transcription. Thus, our data demonstrate that ZBTB7A is an essential regulator in cisplatin-induced apoptosis, and the ZBTB7A-LINC00473-IL24 signaling axis plays an important role in regulating osteosarcoma chemoresistance.

Figure 2. ZBTB7A repressed LINC00473 expression. (A) U2OS cells with or without knocked down ZBTB7A were treated with 10 μM cisplatin for the indicated times. The filtered lncRNA array data were subjected to unsupervised hierarchical clustering analysis. The metric was set as the Euclidean distance. (B and C) U2OS and U2OSR cells with or without knocked down ZBTB7A were treated with cisplatin as indicated and the mRNA levels of LINC00473 were analyzed by qRT-PCR. The protein levels of ZBTB7A were detected by Western blotting. The data represent the mean ± SD of three independent experiments. **P < .01, ***P < .001 versus CTR. (D) U2OS cells with or without overexpressed ZBTB7A or theR399L mutant were treated with cisplatin as indicated. The mRNA level of LINC00473 was analyzed by qRT-PCR. The data represent the mean ± SD of three independent experiments. **P < .01 versus CTR. (E) Schematic illustration of pGL3-based reporter constructs used in luciferase assays to examine the transcriptional activity of LINC00473. (F) The promoter of LINC00473 (F1) was transfected into U2OSR cells with or without ZBTB7A knockdown. The cells were then treated with cisplatin. Luciferase activity was measured by the luciferase assay. The data represent the mean ± SD of three independent experiments. **P < .01 versus CTR. (G) The promoters of LINC00473 (F, F2, F3) were individually transfected into U2OSR cells with or without knockdown ZBTB7A, and then the cells were treated with cisplatin. Luciferase activity was measured. The data represent the mean ± SD of three independent experiments. ***P < .001 versus CTR. (H) ChIP analysis showed the binding of ZBTB7A to the promoter of LINC00473. An isotype-matched IgG was used as a negative control. (I) Schematic illustration of pGL3-based reporter constructs used in luciferase assays to examine the transcriptional activity of LINC00473. The dots indicated the ZBTB7A binding sites. (J) The promoters of LINC00473 WT and mutants (MUT1, 2, 3) were transfected into U2OSR cells with or without knockdown ZBTB7A, and then the cells were treated with cisplatin. Luciferase activity was measured. The data represent the mean ± SD of three independent experiments. ***P < .001 versus CTR.
Materials and Methods

Cell Culture and Reagents

The human osteosarcoma cancer cell lines U2OS and MG63 were obtained from the American Type Culture Collection. U2OS cells were cultured in DMEM with 10% fetal bovine serum (FBS; ExCell Bio, Lot: FSP500). MG63 cells were cultured in EMEM medium with 10% fetal bovine serum (FBS; ExCell Bio, Lot: FSP500). The medium was renewed every day, and cells were passaged before reaching confluence. The following antibodies were used in this study: antibody against GAPDH (Santa Cruz Biotechnology, Dallas, TX; SC-25778); caspase 3 antibody (Cell Signaling Tech, 9662); PARP (Santa Cruz Biotechnology,
RNA Interference and Virus Infection

RNA interference was performed as previously described. The shRNA was purchased from Sigma. The sequences targeting ZBTB7A-1 were 5'-CCACTGAGAACAACACTATT-3' and ZBTB7A-2 5'-GACCTGTAGAGATGGAGCT-3'; and ZBTB7A-3 5'-CATCGTGTCACAAATGGAGTTGAAGG-3'. The sequences targeting LINC00473 RNA level detected by qRT-PCR (F and I). The data represent the mean ± SD of three independent experiments. *P < .05, **P < .01, ***P < .001 versus CTR. (J-L) LINC00473 was inhibited and the cell viability was analyzed by the CKK8 assay. LINC00473 RNA level was detected by qRT-PCR. The data represent the mean ± SD of three independent experiments. *P < .05, **P < .01, ***P < .001 versus CTR.

Real-Time RT-PCR and RT-PCR

Total RNA was isolated using Trizol (Invitrogen). One microgram of total RNA was used to synthesize cDNA using the PrimeScriptTM RT reagent kit (TaKaRa, RR047A) according to the manufacturer's instructions. The primers were as follows: actin: F: 5'-GACCTGAGAACAACACTATT-3' and R: 5'-GACCTGTAGAGATGGAGCT-3'; IL24: F: 5'-CATCGTGTCACAAATGGAGTTGAAGG-3' and R: 5'-CATCGTGTCACAAATGGAGTTGAAGG-3'; and LINC00473: F: 5'-AAACGCGAACGTGAGCCCCG-3' and R: 5'-AAACGCGAACGTGAGCCCCG-3'. The sequences targeting LINC00473: F: 5'-AAACGCGAACGTGAGCCCCG-3' and R: 5'-AAACGCGAACGTGAGCCCCG-3'. The sequences targeting LINC00473 RNA level detected by qRT-PCR (L). The data represent the mean ± SD of three independent experiments. *P < .05, **P < .01, ***P < .001 versus CTR. (M-O) LINC00473 was overexpressed in U2OS cells with or without ZBTB7A overexpression, and then the cells were treated with cisplatin as indicated. The whole cell protein extract was then incubated with RIP wash buffer containing magnetic beads conjugated with human anti-C/EBPβ antibody or rabbit immunoglobulin G (IgG) control. The protein in the samples was digested with proteinase K, and the immunoprecipitated RNA was isolated. Finally, purified RNA was subjected to qRT-PCR analysis to demonstrate the presence of LINC00473.

Microarray and Computational Analysis. Arraystar Human LncRNA Microarray v3.0 is designed for the global profiling of human LncRNAs and protein-coding transcripts. The sample preparation and microarray hybridization were performed based on the manufacturer's standard protocols. Briefly, 10 quality mRNA samples from each group were purified from total RNA after the removal of rRNA using an mRNA-ONLY Eukaryotic mRNA Isolation Kit (Epicenter Biotechnologies, USA). Each sample was amplified and transcribed into fluorescent cRNA along the entire length of the transcript without 3' bias utilizing a random priming method. The concentration and specific activity of the labeled cRNAs (pmol Cy3/μg cRNA) were measured by NanoDrop ND-1000. Then, 1 μg of each labeled cRNA was fragmented by adding 5 μl of 10× blocking agent and 1 μl of 25× fragmentation buffer, heated to 60°C for 30 minutes, and diluted with 25 μl of 2× GE hybridization buffer. Fifty microliters of hybridization solution was dispensed into the gasket slide and assembled to the Human LncRNA Array v3.0 slide (8 × 60 K, Arraystar). The slides were incubated for 17 h at 65°C in an Agilent hybridization oven and then washed, fixed, and scanned using the Agilent DNA Microarray Scanner (part number G2505C). Approximately 30,586 LncRNAs and 26,109 coding transcripts collected from the most authoritative databases, such as RefSeq (release 55), UCSC Human (GRCh37/hg19), GENCODE 13, and lncRNAdb (2.0), were detected using the microarray. Agilent Feature Extraction software (version 11.0.1.1) was used to analyze acquired array images. Quantile normalization and subsequent data processing were performed using the GeneSpring GX v12.0 software package (Agilent Technologies). Protein-coding genes were searched for differentially expressed LncRNAs using the UCSC Genome Browser. Genes transcribed within 300 kb were considered to represent nearby coding genes. The microarray work was performed by KangChen Bio-tech, Shanghai, China.

Protein Identification and Quantitation

RIP. RIP was performed using the EZ-Magna RIP kit (Millipore, USA) following the manufacturer's protocol. U2OS cells at 80% to 90% confluence were collected and lysed in complete RIPA buffer. The whole cell protein extract was then incubated with RIP wash buffer containing magnetic beads conjugated with human anti-C/EBPβ antibody or rabbit immunoglobulin G (IgG) control. The protein in the samples was digested with proteinase K, and the immunoprecipitated RNA was isolated. Finally, purified RNA was subjected to qRT-PCR analysis to demonstrate the presence of LINC00473.

Statistics and Data Analyses. The data are expressed as the mean ± SD, and statistical evaluation was performed using one-way analysis of variance. Values of P < .05 were considered statistically significant.

**Figure 3.** ZBTB7A enhanced cisplatin resistance by repressing LINC00473. (A-C) U2OS cells with or without knockdown LINC00473 were treated with cisplatin as indicated. Cell lysates were then subjected to Western blotting analysis using the indicated antibodies (A). Cell viability was analyzed by the CKK8 assay (B). LINC00473 RNA level was detected by qRT-PCR. The data represent the mean ± SD of three independent experiments. *P < .05, **P < .01, ***P < .001 versus CTR. (D-I) U2OS and U2OSR cells with or without LINC00473 overexpression were treated with cisplatin as indicated. Cell lysates were subjected to Western blotting analysis using the indicated antibodies (D and G). Cell viability was analyzed by the CKK8 assay (E, H). The LINC00473 RNA level was detected by qRT-PCR (F and I). The data represent the mean ± SD of three independent experiments. *P < .05, **P < .01 versus CTR. (J-L) LINC00473 was inhibited using shRNA in U2OSR cells with or without knockdown ZBTB7A, and then the cells were treated with cisplatin as indicated. Cell lysates were subjected to Western blotting analysis using the indicated antibodies (J). Cell viability was analyzed by the CKK8 assay (K). LINC00473 RNA level was detected by qRT-PCR (L). The data represent the mean ± SD of three independent experiments. *P < .05, **P < .01 versus CTR. (M-O) LINC00473 was overexpressed in U2OS cells with or without ZBTB7A overexpression, and then the cells were treated with cisplatin as indicated. Cell viability was analyzed by the CKK8 assay (N). The LINC00473 RNA level was detected by qRT-PCR (O). The data represent the mean ± SD of three independent experiments. *P < .05, **P < .01, ***P < .001 versus CTR.
Results

ZBTB7A Inhibited Cisplatin-Induced Apoptosis in Osteosarcoma

To assess the effect of ZBTB7A on cisplatin-induced apoptosis in osteosarcoma, we first analyzed the expression levels of ZBTB7A in cisplatin-resistant U2OS cells (U2OSR1-10). Compared with the control cells, the protein level of ZBTB7A was increased in most of the cisplatin-resistant cells, particularly in clone 10 (Figure 1A). Thus, only U2OSR10 was used in subsequent functional studies. For convenience, U2OSR10 is hereafter referred to as U2OSR. After that, we detected the protein levels of ZBTB7A in response to cisplatin treatment in U2OS and U2OSR cells and found that the expression...
of ZBTB7A was reduced in U2OS cells under cisplatin treatment in a dose- and time-dependent manner (Figure 1, B and C). However, in U2OSR cells, the reduction of ZBTB7A was prevented (Figure 1, D and E). Then, the endogenous ZBTB7A was knocked down in U2OSR and U2OS cells. Compared with the control cells, inhibition of ZBTB7A significantly promoted cell apoptosis in U2OSR and U2OS cells, as indicated by PARP cleavage (Figure 1, F and G). However, overexpression of ZBTB7A inhibited cisplatin-induced apoptosis in U2OS cells (Figure 1H). To further confirm this result, the cell apoptosis was calculated by flow cytometric analyses with PI and Annexin V double staining. As shown in Figure 1, I and J, the apoptotic population was notably increased in ZBTB7A-suppressed cells during cisplatin treatment (approximately 20% versus 8% in the control group) and was decreased in ZBTB7A-overexpressed U2OS cells (approximately 4% versus 10% seen in the control group) (Figure 1, K and L).

Additionally, to test whether ZBTB7A enhanced cisplatin resistance by its transcriptional activity, we generated a zinc finger (R399L) mutant of ZBTB7A, which was shown to be defective in DNA binding [15]. As shown in Figure 1, M and N, unlike the wild-type ZBTB7A, the R399L mutant failed to suppress the cisplatin-induced apoptosis.

**ZBTB7A Transcriptionally Represses IncRNA LINC00473 in Response to Cisplatin Treatment**

To explore the molecular mechanism whereby ZBTB7A contributed to osteosarcoma chemoresistance, we used microarray analysis to compare lncRNA expression profiles between ZBTB7A knockout U2OS cells and control cells after cisplatin treatment. Among the changes in lncRNAs, we found that IncRNA LINC00473 was dramatically increased in ZBTB7A-suppressed cells under cisplatin treatment, which was confirmed by qRT-PCR (Figure 2, A and B). Consistently, inhibition of ZBTB7A expression promoted LINC00473 increase in U2OSR cells (Figure 2C). In contrast, ZBTB7A overexpression suppressed LINC00473 expression. However, the suppression was abolished by the R399L mutant, indicating that the effect of ZBTB7A on LINC00473 was dependent on its transcriptional activity (Figure 2D).

To investigate whether ZBTB7A can directly repress LINC00473 transcription, we first cloned the upstream sequence of LINC00473 and different truncations by PCR and inserted them into the pG3L-based luciferase reporter plasmids. These truncations were named F1 to F3 (0 ~ 383 bp) was essential for the increase (Figure 2E). As shown in Figure 2F, the luciferase activity of the LINC00473 promoter was increased in ZBTB7A knockout U2OSR cells, and the sequence of F3 (0 ~ 383 bp) was essential for the increase (Figure 2G). To further confirm this result, the chromatin immunoprecipitation (ChIP) assay was performed. As shown in Figure 2H, the fragment of F3 was specifically detected in ZBTB7A immunoprecipitates, and the bond was increased after cisplatin treatment.

A previous report has shown that ZBTB7A binds to GC-rich DNA sequences [25]. To further verify the potential sites bound by ZBTB7A, we inspected the sequence of F3 using JASPAR software. Three positive binding sites of ZBTB7A were identified. As shown in Figure 2I, these binding sites were named 1 to 3 based on the distance from the transcription start site, and then a series of pGL3-based luciferase reporter plasmids containing the wild-type ZBTB7A binding regions or different mutants was constructed. As shown in Figure 2J, specific mutations of predicted ZBTB7A binding site 2 attenuated the luciferase activity, indicating that binding site 2 was a potential binding site of ZBTB7A.

**ZBTB7A Inhibits Cisplatin-Induced Apoptosis via Regulating LINC00473 Expression**

To evaluate whether the effect of ZBTB7A on osteosarcoma chemoresistance was regulated by LINC00473, we first knocked down LINC00473 in U2OS cells and found that inhibition of endogenous LINC00473 decreased cisplatin-induced apoptosis and increased cell viability (Figure 3, A-C). Conversely, overexpression of LINC00473 in U2OS and U2OSR cells accelerated cell apoptosis and decreased cell viability (Figure 3, D-I). Then, we decreased LINC00473 in ZBTB7A-suppressed U2OSR cells. As shown in Figure 3, J, K, and L, we found that the inhibition of ZBTB7A promoted cisplatin-induced apoptosis and reduced cell viability, but the effect was diminished when LINC00473 was knocked down. Similarly, overexpression of LINC00473 decreased ZBTB7A-enhanced cisplatin resistance (Figure 3, M-O).

**ZBTB7A Inhibits IL24 Expression Relying on LINC00473**

To determine the molecular mechanism underlying the LINC00473 promotion of cisplatin-induced apoptosis, gene expression profiles in U2OS cells with or without LINC00473 overexpression were analyzed using mRNA microarray analysis (Figure 4A). As shown in Figure 4, B and C, we focused on the altered genes (more than two-fold) involved in regulation of cell apoptosis. Among the changed genes, IL24 was remarkably upregulated in LINC00473-overexpressing cells under cisplatin treatment, which was subsequently confirmed by Western blotting and qRT-PCR (Figure 4, D and E). Similar results were obtained in U2OSR cells (Figure 4, F and G). Furthermore, the expression levels of IL24 were analyzed in U2OS cells with or without LINC00473 knockdown. Compared with the control cells, IL24 was significantly downregulated when LINC00473 was knocked down (Figure 4, H and I).

Based on the observation that ZBTB7A repressed LINC00473 expression, we asked whether ZBTB7A could mediate IL24 expression by LINC00473. As shown in Figure 4, J and K, inhibition of ZBTB7A in U2OSR cells promoted IL24 expression. However,
Figure 5. LINC00473 upregulated IL24 expression via interacting with C/EBPβ. (A) Schematic illustration of pGL3-based reported constructs used in luciferase assays to examine the transcriptional activity of IL24. (B) The promoter of IL24 (P1) was transfected into U2OSR cells with or without LINC00473 overexpression. Luciferase activity was measured. The data represent the mean ± SD of three independent experiments. **P < .01 versus CTR. (C) The promoter of IL24 (P1) was transfected into U2OS cells with or without LINC00473 knockdown. Luciferase activity was measured. The data represent the mean ± SD of three independent experiments. **P < .01 versus CTR. (D) The promoter of IL24 (P1, P2, P3) was transfected into U2OSR cells with or without LINC00473 overexpression. Luciferase activity was measured. The data represent the mean ± SD of three independent experiments. **P < .01 versus CTR. (E and F) C/EBPα and C/EBPβ were individually knocked down in U2OS cells with or without LINC00473 overexpression. The protein and mRNA levels of IL24 were analyzed by Western blotting and qRT-PCR. The data represent the mean ± SD of three independent experiments. *P < .05 versus CTR. (G and H) ChIP analysis showed the binding of C/EBPβ to the promoter of IL24 when LINC00473 was overexpressed or knocked down. An isotype-matched IgG was used as a negative control. (I and J) RIP analysis showed the interaction of C/EBPβ with LINC00473. The data represent the mean ± SD of three independent experiments. **P < .01 versus CTR.
the increase was abolished when LINC00473 was knocked down. Otherwise, overexpression of ZBTB7A suppressed IL24 expression, which was reversed by LINC00473 (Figure 4, L and M).

**LINC00473 Promotes IL24 Transcription via Interacting with C/EBPβ**

To further investigate the mechanism underlying the LINC00473 regulation of IL24 expression, we first examined whether LINC00473 could regulate IL24 expression transcription. We first cloned the promoter of IL24 and inserted it into the luciferase reporter vector (Figure 5A). As shown in Figure 5B, the firefly luciferase activity was higher after LINC00473 overexpression in U2OSR cells. Conversely, inhibition of LINC0047 prevented the upregulation of luciferase activity (Figure 5C).

To determine which part of the IL24 promoter was essential for LINC00473, we separated the promoter into two parts named P2 and P3 (Figure 5A). We transfected them into U2OSR cells with or without overexpressing LINC00473. As shown in Figure 5D, we...
found that the firefly luciferase activity of P1 and P2 was increased in LINC00473-overexpressing cells; however, the increase was abolished when P3 was transfected, indicating that the region of P2 was essential for the regulation of LINC00473.

Previous reports have shown that the transcription factors C/EBPβ and C/EBPβ could bind the region of P2 and promote IL24 expression [26]. Therefore, we asked whether LINC00473 promoted the upregulation of IL24 via these transcription factors. We first knocked down these transcription factors using shRNA and found that the effect of LINC00473 on IL24 disappeared with C/EBPβ knockdown, suggesting that the upregulation of IL24 by LINC00473 relied on C/EBPβ (Figure 5, E and F). To further confirm this result, we next evaluated whether binding of C/EBPβ to the promoter of IL24 was increased by LINC00473. As shown in Figure 5G, the chromatin fragments corresponding to C/EBPβ were increased when LINC00473 was overexpressed. LINC00473 knockdown decreased the binding of C/EBPβ to the promoter of IL24 (Figure 5H). In addition, RNA immunoprecipitation (RIP) was performed to validate the interaction between C/EBPβ and LINC00473. As expected, we observed a significant enrichment of LINC00473 in the C/EBPβ RIP relative to the IgG control RIP (Figure 5, I and J).

**Discussion**

In this study, we report that ZBTB7A is an important regulator of osteosarcoma chemoresistance. ZBTB7A was increased in cisplatin-resistant cells, and elevation of ZBTB7A inhibited cisplatin-induced apoptosis via transcriptionally repressing LINC00473 expression. In addition, we found that LINC00473 could interact with the transcription factor C/EBPβ and facilitated its binding to the IL24 promoter, leading to IL24 increase and decreasing chemoresistance. Therefore, our data indicated that ZBTB7A-mediated LINC00473-C/EBPβ-IL24 plays an important role in osteosarcoma chemoresistance.

ZBTB7A is a POK family transcription repressor that is best known for its pro-oncogenic role in various cancers. Maeda et al. reported that ZBTB7A promoted cellular transformation by suppressing ARF and that ZBTB7A also promoted cell proliferation and lymphoma formation in transgenic mice [12]. Overexpressed ZBTB7A was capable of promoting cell proliferation by regulating p53, p21, and p27 expression [27]. Consistently, we observed that ZBTB7A was increased in cisplatin-resistant cells and elevated ZBTB7A inhibited cisplatin-induced apoptosis.

Recent reports have shown that IncRNAs play an important role in chemoresistance in many cancers [17,28–34]. However, ZBTB7A-mediated IncRNAs have not been reported. Thus, to identify the IncRNAs that were regulated by ZBTB7A in osteosarcoma cells under cisplatin treatment, the cells with or without knocked down ZBTB7A were analyzed using IncRNAs microarray. Long noncoding RNA LINC00473 was identified as a ZBTB7A-regulated IncRNA.

LINC00473, also known as C6orf176, encodes an intergenic IncRNA from the chromosome 6q27 locus. The previous reports have shown that LINC00473 was in response to cAMP signaling and mediates decidualization of human endometrial stromal cells and was highly induced in LKB-inactivated lung cancer cells. Elevated LINC00473 promoted cell growth and survival [1]. However, the role of LINC00473 in chemoresistance of cancer cells has not been explored. Here, we found that LINC00473 was induced by cisplatin and the increase in LINC00473 under cisplatin was transcriptionally inhibited by ZBTB7A, leading to a cisplatin-induced apoptosis decrease.

Studies have indicated that IncRNAs may be involved in various processes, including transcription, splicing, posttranscriptional regulation, organization of protein complexes, cell-cell signaling, and allosteric regulation of proteins [35–41]. LINC00473 was reported to locate to the nucleus in lung cancer cells. Consistently, LINC00473 was also located in the nucleus in osteosarcoma cells, and the treatment with CDDP did not alter the sublocalization of LINC00473 (Supplementary Figure 1). Subsequently, we found that LINC00473 promoted IL24 expression via interacting with the transcription factor C/EBPβ under cisplatin treatment. The interaction between LINC00473 and C/EBPβ facilitated its binding to the promoter of IL24, leading to an increase in IL24 and a decrease in chemoresistance. Furthermore, we found that ZBTB7A enhanced osteosarcoma chemoresistance via repressing the LINC00473-IL24 pathway, which was subsequent proved in another osteosarcoma cell line, MG63 (Supplementary Figure 2). Thus, our data provide an effective therapeutic strategy for use in osteosarcoma treatment.

Supplementary data to this article can be found online at http://dx.doi.org/10.1016/j.neo.2017.08.008.

**Conflict of Interest**

The authors declare that they have no competing interests.

**Acknowledgements**

This research was supported by the National Natural Science Foundation of China (no. 31270999 to Wenzhi Zhao, 81402260 to Chuanchun Han) and the Liaoning Provincial Natural Science Foundation of China (no. 20170540298) to Lu Zhang and (no. 2015020309) to Chuanchun Han.

**References**

[1] Geller DS and Gorlick R (2010). Osteosarcoma: a review of diagnosis, management, and treatment strategies. *Clin Adv Hematol Oncol* 8, 705–718.

[2] Han XG, Du L, Qiao H, Tu B, Wang YG, Qin A, Dai KR, Fan QM, and Tang TT (2015). CXCR1 knockdown improves the sensitivity of osteosarcoma to cisplatin. *Cancer Lett* 369, 405–415.

[3] Yan GN, Lv YF, and Guo QN (2016). Advances in osteosarcoma stem cell research and opportunities for novel therapeutic targets. *Cancer Lett* 370, 268–274.

[4] Ferrari S, Mercuri M, and Bacci G (2002). Comment on “Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols”. *J Clin Oncol* 20, 2910 [author reply 2910-2911].
Fiorini C, Cordani M, Gorte G, Picone D, and Donadelli M (2015). Onconase induces autophagy sensitizing pancreatic cancer cells to gemcitabine and activates Akt/mTOR pathway in a ROS-dependent manner. Biochim Biophys Acta 1853, 549–560.

Li G, Ma D, and Chen Y (2016). Cellular functions of programmed cell death 5. Biochim Biophys Acta 1863, 572–580.

Wen H, Xu WJ, Jin X, Oh S, Phan CH, Song J, Lee SK, and Park S (2015). The roles of IP3 receptor in energy metabolic pathways and reactive oxygen species homeostasis revealed by metabolomic and biochemical studies. Biochim Biophys Acta 1853, 2937–2944.

Dasari S and Tchounwou PB (2014). Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol 740, 364–378.

Wang Y, Zhang L, Zheng X, Zhong W, Tian X, Yin B, Tian K, and Zhang W (2016). Long non-coding RNA LINC00161 sensitises osteosarcoma cells to cisplatin-induced apoptosis by regulating the miR-645-IFT2 axis. Cancer Lett 382, 137–146.

Costoya JA (2007). Functional analysis of the role of POK transcriptional repressors. Brief Funct Genomic Proteomic 6, 8–18.

Liu CJ, Przak L, Fajardo M, Yu S, Tyagi N, and Di Cesare PE (2004). Leukemia/lymphoma-related factor, a POZ domain-containing transcriptional repressor, interacts with histone deacetylase-1 and inhibitscartilage oligomeric matrix protein gene expression and chondrogenesis. J Biol Chem 279, 47081–47091.

Maeda T, Hobbis RM, Merghouh T, Guernaz I, Zelent A, Cordain-Cardo C, Tenaus-Feldstein J, and Pandolfi PP (2005). Role of the proto-oncogene Pokemon in cellular transformation and ARF repression. Nature 433, 278–285.

Shi DB, Wang YW, Xing AY, Gao J, Wu Q, Lou J, and Han C (2015). LRF, a protein-coding RNA induced by p53 mediates global gene repression in the p53 response. Cell 142, 409–419.

Kanduri C (2011). Long noncoding RNA and epigenomics. Adv Exp Med Biol 722, 174–195.

Lee E, Wang J, Yumoto K, Jung Y, Cackowski FC, Decker AM, Li Y, Franceschi RT, Pienta KJ, and Taichman RS (2016). DNM1T regulates epithelial-mesenchymal transition and cancer stem cells, which promotes prostate cancer metastasis. Neoplasia 18, 553–566.

Lizardo MM, Morrow JJ, Miller TE, Hong ES, Ren L, Mendoza A, Halsey CH, Scachter PC, Helman LJ, and Khanna C (2016). Upregulation of glucose-regulated protein 78 in metastatic cancer cells is necessary for lung metastasis progression. Neoplasia 18, 699–710.

Semenza GL (2016). The hypoxic tumor microenvironment: a driving force for breast cancer progression. Biochim Biophys Acta 1863, 382–391.

Yang Z, Guo X, Li G, Shi Y, and Li L (2016). Long noncoding RNAs as potential biomarkers in gastric cancer: opportunities and challenges. Cancer Lett 371, 62–70.

Mammucari C, Raffaello A, Vecellio Reane D, and Rizzuto R (2016). Molecular structure and pathophysiological roles of the mitochondrial calcium uniporter. Biochim Biophys Acta 1863, 2457–2464.

Nicholas NS, Apollonio B, and Ramsay AG (2016). Tumor microenvironment (TME)–driven immune suppression in B cell malignancy. Biochim Biophys Acta 1863, 471–482.

Palmieri F and Monne M (2016). Discoveries, metabolic roles and diseases of mitochondrial carriers: a review. Biochim Biophys Acta 1863, 2362–2378.

Ponting CP, Oliver PL, and Reik W (2009). Evolution and functions of long noncoding RNAs. Mol Cell 43, 904–914.

Weirwald LB, Bellet D, and Dangles-Marie V (2015). Spherical cancer models in tumor biology. Neoplasia 17, 1–15.

Yan M and Juraz P (2016). The role of platelets in the tumor microenvironment: from solid tumors to leukemia. Biochim Biophys Acta 1863, 392–400.